Immunomodulatory impact
Astragaloside IV, computer mouse peritoneal macrophages and Mycobacterium tuberculosis were incubated together to discover the phagocytosis ability of macrophages towards Mycobacterium consumption, and to discover γ-interferon (IFN-γ) and interleukin-1β (IL) in the society tool. -1 β) content. The results revealed that when the dosage of astragaloside IV was 0.2, 0.6, 1.5, and 4.0gL-1 respectively, the copy number of Mycobacterium tuberculosis DNA (TB-DNA) in macrophage phagocytosis of Mycobacterium tuberculosis and the IFN-γ and IL in the supernatant The levels of -1 β were dramatically higher than those in the control group. Astragaloside IV improves the ability of macrophages to phagocytose Mycobacterium tuberculosis. Astragaloside IV can advertise the proliferation and antibody production of computer mouse T and B lymphocytes in vivo and artificial insemination, advertise the proliferation of B cells in the non-thymus-dependent location, the formation of a lot of plasma cells, and advertise the synthesis of antibodies. Cells were not considerably affected.
Body organ protective impact
( 1) Brain safety effect Astragaloside IV has a safety impact on mental retardation caused by short-term focal anemia in mice. Its effect is associated with its antioxidant impact, and it is anticipated to end up being a clinical medicine for the therapy of stroke. Astragaloside IV has a safety impact on the blood-brain obstacle in rats after cerebral ischemia-reperfusion. (2) Renal protective result Astragaloside IV has a particular protective result on kidney damages caused by ischemia-reperfusion. It can successfully protect the kidneys throughout kidney transplantation and enhance the success rate of hair transplant. Moreover, astragaloside IV can down-regulate the healthy protein content and mRNA overexpression of monocyte chemoattractant protein-1 (MCP-1) in kidney tissue. (3) Lung protective impact Astragaloside IV has a specific safety impact on pulmonary ischemia-reperfusion injury in speculative rats, and can minimize lung blockage and focal pulmonary hemorrhage in rats. Astragaloside IV can effectively prevent ovalbumin-induced chronic asthma. (4) Myocardial protective result Astragaloside IV can substantially boost cardiac function in rats with myocardial ischemia and myocardial infarction. This effect is favorably related to dose and time. After sterilized intraperitoneal injection of coxsackie virus (CVB3) right into Balb/C computer mice to create a viral myocarditis version, 9% astragaloside IV was administered intragastrically for 7 days, which can improve the survival rate of mice with myocarditis and minimize collagen synthesis and cardiomyocyte apoptosis. Fatality. (5) Liver safety result Astragaloside IV can prevent collagen synthesis and hepatic stellate cell spreading, and has a considerable inhibitory impact on hepatocyte fibrosis.
Hypoglycemic impact
Kind 2 diabetic person rats were made use of as research subjects to research the governing effect of Astragaloside IV on hepatic sugar enzyme in diabetic rats generated by streptomycin and high-fat diet regimen. The results revealed that astragaloside IV can dramatically lower blood glucose, triglyceride (TG) and insulin levels in rats when provided at dosages of 25 and 50 mg/kg, and hinder related mRNA and healthy protein expression. Additionally, astragaloside IV can prevent TNF-α-induced lipolysis of 3T3-L1 lipocytes, thus reducing cost-free fat (FFA) degrees, enhancing insulin level of sensitivity, and reducing blood glucose and blood lipids.
Anti-apoptotic effect
Astragaloside IV can substantially decrease the apoptosis index of cardiomyocytes in CVB3 viral myocarditis. Astragaloside IV has a particular inhibitory effect on doxorubicin-induced apoptosis of computer mouse bone marrow mesenchymal stem cells (BMSCs), however there is no obvious dosage reliance.
Anti-inflammatory and anti-viral results
Astragaloside IV has a considerable inhibitory impact on xylene-induced ear swelling in mice and exhibits strong anti-inflammatory impacts. Astragaloside IV has anti-hepatitis B infection result After 10 days of medication therapy, the HBV inhibition rates at dosages of 120, 40 and 10 mg/kg were 64.0%, 49.6% and 41.7% specifically. A decline in hepatitis B infection (DHBV) DNA degrees in serum was likewise observed.
Anti-aging effect
The anti-aging impact of astragaloside IV is related to its ability to scavenge cost-free radicals and withstand lipid peroxidation, advertise healthy protein revival, remove nucleic acid metabolic rate disorders, and advertise the expansion and apoptosis of human skin fibroblasts. Astragaloside IV can advertise the spreading of wrinkled and wrinkle-free skin fibroblasts at a reduced focus (5-20mg/ L), promote the synthesis of type I collagen in old and wrinkly, wrinkle-free and aged skin fibroblasts, and decrease creases and wrinkle-free skin. Fibroblast apoptosis price.
Advertise cell expansion
Suitable concentration of Astragaloside IV can advertise the fast expansion of chondrocytes and keep the activity of chondrocytes, providing a brand-new method for cartilage material cells engineering to acquire a large number of seed cells in a brief time period and keep the task of chondrocytes.
Other functions
Astragaloside IV exerts particular anti-cancer task by preventing the expression of Vav3.1 genetics. It prevents the flow of calcium ions right into cells through the NO-cGMP pathway, prevents the launch of intracellular calcium ions, inhibits the tasks of phenylephrine and angiotensin II, and has a particular soothing effect on rat aortic ring vessels and isolated mesenteric arteries.
